Hypertension

January 18, 2022

A retrospective cohort analysis of more than 3000 patients with CKD suggests use of MRAs was significantly associated with a reduction in the need for renal replacement therapy.

January 08, 2022

A recent analysis found patients with benign adrenal tumors and MACS were at an increased risk of cardiometabolic diseases.

December 25, 2021

Each month, our editorial staff compiles a month in review highlighting the most popular content from the past month. December's month in review features new guidelines, FDA news, and more.

December 15, 2021

Released on Dec. 15, the latest scientific statement from the American Heart Association provides a comprehensive overview of the available evidence on topics related to diagnosis, management, and pharmacotherapy for hypertension during pregnancy.

December 09, 2021

The Practical Cardiology editorial staff has compiled a list of 6 noteworthy posters related to cardiology from the Metabolic Institute of America's 19th annual World Congress on Insulin Resistance, Diabetes, and Cardiovascular Disease.

December 06, 2021

A report published in Circulation details per month increases in both systolic and diastolic blood pressure observed during the pandemic as compared with prepandemic periods.

November 19, 2021

The latest data from the digital care transformation program provides insight into effects of digital monitoring programs on helping patients achieve blood pressure and cholesterol goals.

November 08, 2021

Data from the CLICK trial presented at ASN Kidney Week 2021 suggests the use of chlorthalidone could reduce blood pressure by 11 mmHg among patients with stage 4 chronic kidney disease and poorly controlled hypertension.

November 05, 2021

Results of the 6-month follow-up from RADIANCE-HTN TRIO suggest the addition of antihypertensive medications following renal denervation could contribute to further blood pressure lowering in patients with treatment-resistant hypertension.

October 26, 2021

Gregory Weiss, MD, provides perspective on a recent scientific statement from the AHA outlining the role of health systems in promoting optimal adherence to hypertension therapies and helping patients achieve treatment goals.